Cargando…

Thalidomide and its analogues in the treatment of Multiple Myeloma

Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Latif, Tahir, Chauhan, Nabeel, Khan, Rashid, Moran, Andrea, Usmani, Saad Z
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514107/ https://www.ncbi.nlm.nih.gov/pubmed/23210501 http://dx.doi.org/10.1186/2162-3619-1-27

Ejemplares similares

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Chromosome 1q21 abnormalities in multiple myeloma
por: Schmidt, Timothy M., et al.
Publicado: (2021)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

Molecular mechanisms of thalidomide and its derivatives
por: ITO, Takumi, et al.
Publicado: (2020)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma
por: Grima, Maria Angela, et al.
Publicado: (2016)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison
por: Usmani, Saad Z., et al.
Publicado: (2017)

Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
por: Rehman, Suhailur, et al.
Publicado: (2017)

Thalidomide as an effective treatment for adult multiple xanthogranuloma
por: Debois, Deborah, et al.
Publicado: (2018)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
por: von Lilienfeld-Toal, Marie, et al.
Publicado: (2008)

Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma
por: Das, Anupam, et al.
Publicado: (2014)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison
por: Prince, H Miles, et al.
Publicado: (2007)

The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis
por: He, Gan-Lin, et al.
Publicado: (2018)

Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment
por: Popek-Marciniec, Sylwia, et al.
Publicado: (2023)

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects
por: Dredge, K, et al.
Publicado: (2002)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dbtrcq0ukmtt5rleukja41rq63